SE448342B - Farmaceutisk komposition med depaverkan innehallande nicardipin, nicardipinsalt, nifedipin eller indometacin i amorf form - Google Patents

Farmaceutisk komposition med depaverkan innehallande nicardipin, nicardipinsalt, nifedipin eller indometacin i amorf form

Info

Publication number
SE448342B
SE448342B SE8004938A SE8004938A SE448342B SE 448342 B SE448342 B SE 448342B SE 8004938 A SE8004938 A SE 8004938A SE 8004938 A SE8004938 A SE 8004938A SE 448342 B SE448342 B SE 448342B
Authority
SE
Sweden
Prior art keywords
nicardipine
salt
pharmaceutical composition
composition according
nicardipin
Prior art date
Application number
SE8004938A
Other languages
English (en)
Other versions
SE8004938L (sv
Inventor
H Kawata
M Aruga
T Ohmura
T Sonobe
S Yoneya
C Sone
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP8520979A external-priority patent/JPS5649314A/ja
Priority claimed from JP3651480A external-priority patent/JPS5948810B2/ja
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of SE8004938L publication Critical patent/SE8004938L/sv
Publication of SE448342B publication Critical patent/SE448342B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

) 15 20 25 30 35 448, 31112 2 Ändamålet med föreliggande uppfinning är således att åstadkomma en farmaceutisk komposition som har hög löslighet och överlägsen depåverkan genom att blanda ett läkemedel, polyetenoxid och minst ett basämne (l:a komponent) valt bland hydroxipropylmetylcellulosa, hydroxipropylcellulosa, polyvinylpyrrolidon, karboxi- vinylpolymer och hydroxipropylmetylcellulosaftalat.
Denna farmaceutiska komposition kan vidare innehålla minst ett basämne (2:a komponent) valt bland ytaktiva medel och polyetylenglykol.
Den farmaceutiska kompositionen av ett fast läke- mvd~i mflu dvpavurkanlenlrgt ändamålet med förelig- gande uppfinning kan erhållas genom följande metod.
Ett fast läkemedel och ovanstående basämne(n), dvs den l:a komponenten (de lza komponenterna) eller den lza komponenten (de 1:a komponenterna) och den 2:a komponenten (de_2;a komponenterna) löses i ett organiskt lösningsmedel, såsom metanol, etanol, kloroform, di? klormetan, ensamma eller i kombination, eller vatten och därefter avlägsnas lösningsmedlet. Avlägs- nandet av lösningsmedlet genomföras genom torkning under reducerat eller normalt tryck, spraytorkning, granuleringstorkning i fluidicerad bädd eller lyofi- lisering etc. Genom ovanstående förfaranden erhålles ett fint pulver eller granuler med fin kornstorlek, i vilka ett fast läkemedel är löst eller homogent dis- pergerat i amorf form i basämnet (basämnena). Därefter tillsättes polyetenoxid till det fina pulvret eller granulerna med liten kornstorlek som sålunda erhållits följt av blandning av dessa för att åstadkomma den farmaceutiska kompositionen med depåverkan enligt föreliggande uppfinning.
Denna farmaceutiska komposition kan även erhållas genom att tillsätta polyetenoxid och basämnet (bas- ämnena), dvs den lza komponenten (de l:a komponenterna) eller den lza komponenten (de lza komponenterna) och den 2:a komponenten (de 2:a komponenterna) sam- 'fßx & 'w <1 glo 15 20 '25 _30 35 . 448 542 3 tidigt- varvid polyetenoxid blir homogent löst eller I, dispergerat med ett *fast läkemedel i basämnet (bas- ämnena).
Som det fasta läkemedlet i förgliggande uppfinning ':aÜVänÖS ett läkemeåel med låg eller hög löslighet *alltefter vad som önskas för att kvarhållas i mag-tarm- kanalen nnder lång tid.-Dessa läkemedel omfattar nicardi- Pin, ett nicardipínsalt, exempelvis nicardípinväteklorid,o nifedipin eller indometacin. 7 _'fSom det ytaktiva medlet som det 2:a ämnet kan nämnas anjoniska vtaktiva medel, såsom natriumalkyl- sulfat, nonjoniska ytaktiva medel, såsom polyokietylen- sorbitanfettsyraester, polyoxietylenfettsyraester, _nolyoxietylenricinoljaderivat etc. _ ,'Blandningsförhållandet för varje komponent i den-farmaoeutiska'kompositionen'varierargalltefter typen av det fiasta läkemedlet eller dess administra- tionsdos. Vanligen är det lämpligt att använda 0,5 - 20: viktdelar, företrädesvis l -llÖ viktdelar av den l:a komponenten (de l;a komponenterna), 0,05 - lo vikt- ïdelar, företrädesvis 0,1 - 5 viktdelar av den 2:a komponenten (de 2:a komponenterna), per_viktdel av gadet fasta läkemedlet. Blandningsförhållandet för gpolyetenoxid är lämpligen 0,1 - 50 viktdelar, före- trädesvis 0,5 -'30 viktdelar per viktdel av den totala mängden fast läkemedel, lta komponent (lza komponenter) eoch°2:a'komponent'(2:a komponenter)§ Den farmaoeutiska kompositionen med depåverkan §>som sålunda erhållits kännetecknas av att polyeten- oxid är inblandad i det fina pnlvret eller granu- g-lerna med den Jilla kornstorleken, 1 vilket ett fast *läkemedel föreligger i amorf form. Hittills har poly-- etenoxid"använts_som ett beläggningsmedel eller ett bindemedel vid framställningen av farmaceutiska kom- positioner, men_det har inte angivits att en farma- ceutisk komposition med depåverkan kan erhållas genom 448 542? 10 15 20 25. 4 latt blanda in palyetenoxid l ett fast läkemedel l amerf form; såsom vid fiöreliggande fippfinning. Den farfiacettiska kompesitienen med depåverkan enligt föreliggande uppfinning kan inte endast åstadkomma ä depåverkangütan_även god adsorberingsföpmåga för ett läkemedel, varför een get hög biotillgänglighet e ,(ÜbieaVailabilityf). __Depifarmaceptiska tempositiohenwenligt_ferelig~ 7 gahde_fippfihning_kan i fitaktiken användas genom att formas till pplVerL_g;anpler} tabletter} piller, kaps- _la; Få konyentipnellt gått. Via Étamställningen av .eådana formuleringar kafi man_lämpligen använda utsfiäd- hing§medel,_bindemedel) viekositetsfiöjande medel etc.
Alltefter slaget aV_eet fiaeta läkemefilet kan vidare en fiörenlag för $pap§'fipp1öšfilng_av läkemedlet till: sättas i den fia;maceutiska komeositionen eller kan ,.en behanqligg fö; upplösningen av kompositionen i tarmkanalep/anväadasf N __ _ 7 _ ,Amorf Qicardipih som använde vid föreliggande upp- .fiinning kan framställas genefi ftiktionspulvlisering av nicardipinpulgeç,Nfö;eträdesVis¿genóm pulvrieering av "nicardipinpulvret till_fint pulver med användñing av en kplkvatg elle: en vibrerande kulküatn. _ a ¿t¿íl_pulvtiseringssteget är det lämpligt att till- :eätta vissa ämnen fö: att fiinška vidhäftningenióch fsammanfiörandet till en massa av nicardifiin, så att nicardipin fullstäedigt kan fiultrišeras till fint pulver. 7 »Exempel.på eådana ämnen är kalciumlaktat, "TC-5" 30 ssalia. ~ losa); etc. Ändringen av nicardipin eller dess salt ftill den amotfa formen i pulyriseringssteget kan be- (va;pmä:ke,_Shineteu-Kagakfi.Kógyo*Ce., beståndsdel: h§drQxipropylmetylcellulosaf, "Avicel“ (varumärke,' gAsahikasei Kogyo Co., beetåndsdell kristallin cellu- 6:a kräftas medelst röptgenstxålediffraktion; f» gviktandelen nicardípinpulvek kan regleras på lämpligt sätt och är vanligen 5-90 %,'föfeträdesvis .1 (ß.
Q» 10 15 -20 25 ao KI35 44ags4zg _ _ 5 *lO-70 %, helst 20-40 % av kompositionens totala vikt.
Nicardipinpulvret är vanligen i kristallin form och nicardipinväteklorid t ex är en kristall med en smält- punkt av~l68-l70°C, Men det är möjligt att framställa *amorf nicardipin i syntessteget eller reningssteget vid framställning av nicardipin och i detta fallet kan den bildade amorfa nicardipinen användas som den är för framställning av kompositionen enligt före- liggande uppfinning., I I KV net fina pnlvret av amorf nicardipin i förelig- gande uppfinning kan ge depâverkan endast genom an- bringande av någon beläggning för att undvika sönder- delning och upplösning i magsäcken. Vidare kan det ge en sådan verkan genom tillsats av ett pH-beroende medel, ett viskositetsökande medel eller ett vattenolösligt medel före eller efter pulvriseringssteget. _Som_det pH-beroende medlet kan nämnas baser som är llösliga i tarmkanalen, såsOm Cellulosaacetatftalat, hydroxipropylmetylcellulosa, "Eudragit" L, S, RL och RS (varumärkenf Rohm and Haas.Co., beståndsdel: akryl- syrametakrylsyraestersamnolymer eller metakrylsyra- I metakrylsyraestersampolymer) etc. Som det viskositets- höjande:medlet kan användas polyetenoxid, "Carbopol" (varnmärke, B.F. Goodrich Co., beståndsdel: karboxi- vinylpolymer),cnatriumpolyakrylat, natriumarginat, karboximetylcellulosakaloium, karboximetvlcellulosa- netrium; pelyetyienglykeig(mo1eky1vikt= eooo - zo ooo) etc. Som det vattenolösliga medlet kan användas kris- tallin cellulosa (t ex "Avicel", varumärke), kalcium- fosfat etc. ,_ 7 ' “Viktandelen av de-ovanstående medlen kan lämpligen regleras i enlighet med de praktiskt använda bland- _ningarna¿ Absorptionsmängden nioardipin kan regleras genom nicardipinensgpulvriseringsgrad eller den till- satta mängden av ovanstående medel, så att det är ”a möjligt ett reglera uppträdande: av den medicinska 4487542 i 6 effekten och den effektiva tiden för nicardipin.
Den farmacentiska_kompositionen enligt förelig- A gande uppfinning formas till granuler; tabletter, piller, kapslar etc på konventionellt sätt. Vid fram- ställningen av dessa preparat kan man tillsätta ut- 'spädningsmedel,»bindemedel, uppblandningsmedel etc. _Föreliggande uppfinning förklaras vidare i detalj med följande exempel. v; @ 3 2 4 3 oo 4 å.. ./_ om.,~_wo_H_ .ïmm __ m6” _ mflw _ ïfiä oâw ïßfi _ 123 .oáofi wåms 3 w w.ä=w_ü&@a_ _ _ _ _ » __ _ _ _ _ _ _ _ _ _ _ _ _ __.Hwumw_.~=« _ _ _ __ _ _ _ åaå Wšš mfi..m_N_ _ _ __.|_ Ü l.. _ N._m_ __._U«O . .MÄN . .Nim , mßw _ nflß _ __ .WHOWW-fimwvw _ mfwåmuvw __ 3 ___ ß ofl 1: m _ ß w z p m __ n :_ ä _ wo? ufišzf »på åwwwmww __ _ _ _ _ šwfiv _ _ www dmvwsx _ Hund! mwfiw. __ _ _ _ _ __ .__ MHMQGSS_ .ÜUÄ sOflumHMm-.nflwëwm HmnO ...ufw .ufiwflofinfw floflvmnflfiwufiom 448 34:e* 10 '20 30 35 l_ExEnPEL 1 7 organiska lösningsmedel destillerades av genom spray~ .' 8 ' - I 01000 g av en blandning av diklorometan och metanol (viktförhålianaa 1:1) saraaa till an.b1ananing av so g niçardipinväteklorid och lO0 g hydroxipropylmetylf' ? dcellulosa för *att-åstadkomma en lösning. Lösningens torkning för åstadkommande av ett finkornigt pulver.
Till SO g av det sålunda erhållna finkorniga pulvret ' sattes 30»g finkornigt pulver av polyetenoxid och '3,3 q talk och dessa blandades homogent; Kapslar fram- fställdes genom att fylla 250 mg av blandningen i var loch.en av kanslar nr l. I I 0 ' t3000 o av en blandning av diklorometan och metanol gviktförhaiianaa 1:1) sattes till an blandning av loo g indometaçin fl-(p~klorobensoyl)-Semetoxi-2-metylindole -3-ättiksyra], 200 g ñydroxipropylcellulosa och 20 g polyetenoxid för att åstadkomma en lösning. Det orga- nisba lösningsmedlet i lösningen destillerades av genom spravtprkning för åstadkommande avsett fin- 'kornigt pulver, Till 160 g av det sålunda erhållna finkorniga pulvret sattes 80 Q polyetenoxid ooh l0 g talk och dessa blandades hombgent. Kapslar fram? ' _ ställdes genom att fylla 250 g av blandningen i var aoch en av kapslar nr la 400 q metanol sattes till en blandning av 20 g nicardipinväteklorid, 40.g hydroxipropylmetylcellu- losaftalat och 10 Q polysorbat 80 för att åstadkomma en.lösning._Det:erganiska'lösningsmedlet-i_lösningen destillerades av-genom torkning under reduçerat tryck? för åStadkommande_av ett fast material. Det fasta materialet pulvrlserades till ett finkornigt pulver.
Till-35 g av det sålunda erhållna_finkorniga pulvret sattes 105 g finkristallin cellulosa,:80-q polyeten~ »àV fi' a'oxid och l0»g talk och dessa blandades homogent.« Kapslar framställdes genom att fylla 230 mg av bland- ningen i var och en av kapslar nr l. _d I ~' 0%- *v 10 lo 448 342 Eš§ME§ë_É _ _ _ ' " 40 g av det kristallina pulvret av nicardipin- aväteklorid{ 200 g_kalciumlaktat och 20 g polyeten-. oxid l8 pulvriserades i 16 h medelst en vibrerande - kulkvarn, varigenom kristallerna av nicardipinväte- -klorid ändrades till amorf form. Med användning av en granulator med 'flnidiserad bädd ("Uniglat", _varumärke; Okawara Seisakusho Co.), flnidiserades 'l95 g av det sålunda erhållna pulvret och 150 g f“Kalica GS" (varumärke, Kyowa Kagaku Kogyo Co., beståndsdel: vattenfri fosforsyravätekalcium), 7 sprayades med en lösning av 20 g polyetenoxid-18 i 3000 ml metylenklorid och behandlades på konven- tionellt sätt för att åstadkomma fina granuler.
Kapslar framställdes genom att fylla 365 mg av de sålunda erhållna fina granulerna i var ocn en av kapslar nr l på konventionellt sätt.

Claims (6)

e 448 342 1:! 10 15 20 25 30 in a d av att friktionspulvriseringen har genomförts ' ¿ .medelst en kulkvarn eller en yibrerande kulkvarn. V 10 I PATENTKRAV . . _ Z . l
1. Farmaceutisk komposition med depaverkan, ak ä n - _ n eft e c k n a d aav'att den innehåller ett fast läke- é medel i amorf form, blandat med polyetenoxid och minst ett av ämnena hydroxipropylmetylcellulosa, hydroxipropyl- cellulosa, polyvinylnyrrolidon, karboxivinylpolymer och hydroxipropylmetylcellulcsaftalat, varvid läke- medlet är nicardipin [2,6-dimetyl-4-(3'~nitrofenyl)-l,4- -dihydropyridin-3,5-dikarhoxylsyra-3-metyleeter-5~ßf -(N-bensyl-N-metylamino)-etylester], ett nicardipinsalt, fnifedipin '[l,4-dihydro-2,6edimetyl-4-(o-nitrofenyl)- -3,5-pyridin-dikarboxylsyredimetylester] eller indometacin [1-(p-klorobensoyl)-54metoxi-2-metylindol-3-ättiksyra].
2. , Farmaceutisk komposition enligt krav l, k ä n n e t e c k n¶a d av att den innehåller ett, två eller tre av ämnena hydroxipropylmetylcellulosa, hydroxipropylcellulosa, polyvinylpyrrolidon; karboxi- vinylpolymer och hydrçxiprcpylmetylcellnlosaftalat.
3. Farmaceutisk komposition enligt krav l eller 2, k ä n n e t e c kwn a d av att den även innehåller en eller tvâ av ämnena ytaktivt medel och polyetylen- glykol. d_ d d
4. Komposition enligt ett eller flera av kraven l-3, k.ä n n e t e c k n a d av att det amorfa fasta läkemedlet är amorf nicardipin eller dess salt;
5. Komposition enligt krav 4; k ä n n e t e c k* n a d av att den amorfa nicardipinen eller dess salt har erhållits genom friktionspulvrisering av nicar- dipin eller dess salt till fint pulver,t I d
6. Komposition enligt krav S, k ä n n est e c k-
SE8004938A 1979-07-05 1980-07-04 Farmaceutisk komposition med depaverkan innehallande nicardipin, nicardipinsalt, nifedipin eller indometacin i amorf form SE448342B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8520979A JPS5649314A (en) 1979-07-05 1979-07-05 Lasting pharmaceutical composition having prolonged action and its preparation
JP3651480A JPS5948810B2 (ja) 1980-03-22 1980-03-22 ニカルジピン持続性製剤用組成物

Publications (2)

Publication Number Publication Date
SE8004938L SE8004938L (sv) 1981-01-06
SE448342B true SE448342B (sv) 1987-02-16

Family

ID=26375569

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8004938A SE448342B (sv) 1979-07-05 1980-07-04 Farmaceutisk komposition med depaverkan innehallande nicardipin, nicardipinsalt, nifedipin eller indometacin i amorf form

Country Status (9)

Country Link
US (3) US4343789A (sv)
CA (1) CA1146866A (sv)
CH (1) CH648484A5 (sv)
DE (1) DE3024858C2 (sv)
ES (1) ES493152A0 (sv)
FR (1) FR2460667A1 (sv)
GB (1) GB2053681B (sv)
IT (1) IT1132169B (sv)
SE (1) SE448342B (sv)

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
MX7567E (es) * 1981-12-23 1989-10-27 Yamanouchi Pharma Co Ltd Procedimiento para recubrir nicardipina de accion prolongada
US4758437A (en) * 1981-12-23 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Composition for long acting nicardipine preparation and process of producing the composition
US4525345A (en) * 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPS597163A (ja) * 1982-07-02 1984-01-14 Yamanouchi Pharmaceut Co Ltd 抗動脈硬化剤
US4522956A (en) * 1982-07-29 1985-06-11 Richardson-Vicks Inc. Poly(ethylene oxide)/polyethylene glycol-containing hydrophilic denture adhesive
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
US4832952A (en) * 1983-07-07 1989-05-23 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4777048A (en) * 1983-07-07 1988-10-11 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
ZA836030B (en) * 1983-08-16 1985-02-27 Verex Lab Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) * 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
EP0159604B1 (en) * 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
HU197201B (en) * 1985-10-01 1989-03-28 Sandoz Ag Process for producing oral pharmaceutical compositions of controlled solubility of the active components
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
AU3432689A (en) * 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5221535A (en) * 1989-11-13 1993-06-22 Nova Pharmaceutical Corporation Sustained release formulations of insect repellent
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5211959A (en) * 1990-01-11 1993-05-18 Japan Atomic Energy Research Institute Processes for producing slow-release powders
JPH03232817A (ja) * 1990-02-07 1991-10-16 Showa Yakuhin Kako Kk 貼付剤
ES2093106T3 (es) * 1990-07-19 1996-12-16 Otsuka Pharma Co Ltd Preparacion solida.
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
TW212139B (sv) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
TW209174B (sv) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
DE69332081T2 (de) * 1992-09-18 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelzubereitung mit verzögerter freisetzung
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
HUP9700322A3 (en) 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
NZ286451A (en) * 1996-04-24 1998-04-27 Bernard Charles Sherman Controlled release pharmaceutical composition containing granules comprising drug, water-insoluble polymer and meltable carrier
US5855615A (en) * 1996-06-07 1999-01-05 Menlo Care, Inc. Controller expansion sphincter augmentation media
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
EP0859603B1 (en) 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US7049346B1 (en) * 1996-08-20 2006-05-23 Menlo Care Div Of Ethicon, Inc. Swollen hydrogel for sphincter augmentation
US5813411A (en) * 1996-08-20 1998-09-29 Menlo Care, Inc. Method of deforming tissue with a swollen hydrogel
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
BR9815499A (pt) 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IN186245B (sv) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
CN1285738A (zh) * 1997-11-12 2001-02-28 泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 卡维地洛的新的口服剂型
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
HUP9902351A3 (en) * 1998-07-22 2001-01-29 Pharma Pass L L C Irvine Solid compositions containing metoprolol and process for producing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
GB2381453A (en) * 1999-08-31 2003-05-07 Bradford Particle Design Ltd Active/polymer coformulations
KR100463496B1 (ko) * 1999-09-30 2005-01-06 펜웨스트 파머슈티칼즈 컴파니 고가용성 약물용 서방성 메트리스 시스템
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6423332B1 (en) 2000-05-26 2002-07-23 Ethicon, Inc. Method and composition for deforming soft tissues
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
CN1537005A (zh) * 2001-04-26 2004-10-13 �����Ƹ���ʽ���� 无定形头孢托仑匹伏克西路组合物及其制备方法
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
JP4547148B2 (ja) * 2001-06-22 2010-09-22 ベンド・リサーチ・インコーポレーテッド 非晶質薬剤の吸着物の医薬組成物
EP1411899B1 (en) * 2001-08-01 2009-03-11 Novartis AG Taste masking composition
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003249474A1 (en) 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7135436B2 (en) * 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1696887A1 (en) * 2003-11-14 2006-09-06 Pfizer Products Inc. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP2548894A1 (en) 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
KR100691608B1 (ko) * 2005-02-21 2007-03-12 (주)나노하이브리드 염기성 고분자가 첨가된 유리 염기형 약물과 층상형 규산염의 하이브리드 및 그의 제조방법
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2007136085A1 (ja) 2006-05-23 2007-11-29 Mochida Pharmaceutical Co., Ltd. スピロ四環系化合物
RU2009103660A (ru) * 2006-07-07 2010-08-20 Тева Фармасьютикал Индастриес Лтд. (Il) Твердые фармацевтические композиции, включающие тадалафил и по меньшей мере один носитель
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8071119B2 (en) * 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US20080292680A1 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed polymer particles for controlled release ophthalmic medications
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
JP5489997B2 (ja) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
TW201002705A (en) * 2008-03-31 2010-01-16 Metabolex Inc Oxymethylene aryl compounds and uses thereof
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
MX2011002847A (es) * 2008-09-19 2011-04-07 Activus Pharma Co Ltd Polvo de compuesto organico combinado para uso medico y metodo de produccion y suspension del mismo.
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
WO2011041595A1 (en) * 2009-09-30 2011-04-07 Microdose Therapeutx, Inc. Methods and compositions for treatment of raynaud's phenomenon
WO2011041154A1 (en) * 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
CA2799708A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
EP2585048B1 (en) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3077388A1 (en) 2013-12-05 2016-10-12 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
CA2938994A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
EP3119757B1 (en) 2014-03-17 2018-05-16 Pfizer Inc Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
KR102629269B1 (ko) 2015-02-27 2024-01-24 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
US11883381B2 (en) 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP3493807A1 (en) 2016-08-03 2019-06-12 CymaBay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
KR102605329B1 (ko) 2016-08-26 2023-11-22 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2018163066A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
US11382897B2 (en) 2017-11-07 2022-07-12 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
WO2019094772A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
JP7414282B2 (ja) 2017-12-07 2024-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｎｓｄファミリー阻害物質及びそれによる治療の方法
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
EP4155293B1 (en) 2018-06-07 2025-07-30 The Regents of The University of Michigan Prc1 inhibitors and methods of treatment therewith
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
US12246042B2 (en) 2018-08-29 2025-03-11 Myos Corp. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
BR112021003039A2 (pt) 2018-08-31 2021-05-18 Pfizer Inc. combinações para o tratamento de nash/nafld e doenças relacionadas
US12251405B2 (en) 2018-10-03 2025-03-18 Myos Corp. Spray dried follistatin product
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
AU2020240015B2 (en) 2019-03-15 2025-10-09 Unicycive Therapeutics Inc. Nicorandil derivatives
EP3956031A1 (en) 2019-04-19 2022-02-23 Pfizer Inc. Anti-proliferative agents for treating pah
US12611401B2 (en) 2019-05-20 2026-04-28 Pfizer Inc. Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
CA3144848C (en) 2019-06-28 2023-11-21 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
PE20231215A1 (es) 2020-06-09 2023-08-17 Pfizer Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
EP4178571A4 (en) 2020-07-10 2024-07-17 The Regents Of The University Of Michigan GAS41 INHIBITORS AND METHODS OF USE
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023034184A1 (en) 2021-08-31 2023-03-09 Cerespir Incorporated Co-crystals
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
AU2022403203B2 (en) 2021-12-01 2025-09-25 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
CA3241470A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
CA3242316A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
US20250353854A1 (en) 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
IL319486A (en) 2022-10-07 2025-05-01 Pfizer HSD17B13 Inhibitors and/or Retarders
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
CN120129681A (zh) 2022-10-18 2025-06-10 辉瑞大药厂 含Patatin样磷脂酶结构域的蛋白3（PNPLA3）调节剂
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
AU2023363975A1 (en) 2022-10-19 2025-05-22 Myos Corp. Myogenic compounds
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
JP2025541231A (ja) 2022-12-16 2025-12-18 ファイザー・インク ３－フルオロ－４－ヒドロキシベンズアミド含有阻害剤および／または分解剤ならびにそれらの使用
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2025072556A1 (en) 2023-09-26 2025-04-03 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives
WO2025208111A1 (en) 2024-03-29 2025-10-02 Biomea Fusion, Inc. Heterocyclic glp-1r agonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL44885C (sv) * 1935-11-09
US2540253A (en) * 1949-02-08 1951-02-06 Merck & Co Inc Granulation process
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
GB1050396A (sv) * 1964-03-31
US3297804A (en) * 1964-05-19 1967-01-10 Ono Pharmaceutical Co Method of filling hard capsules with granules by the open-mouth-down punching method
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3692896A (en) * 1968-06-14 1972-09-19 Isumura Juntendo Co Ltd Process for the preparation of water-soluble tablets
NL6808619A (sv) * 1968-06-19 1969-12-23
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
DE2400819C2 (de) 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
JPS5438167B2 (sv) * 1974-04-27 1979-11-19
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4180559A (en) * 1978-01-05 1979-12-25 Richardson-Merrell Inc. Coated 1-(2-chlorodibenzo[b,f]oxepin-10-yl)-4-methylpiperazine compositions
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
DE2847237A1 (de) 1978-10-31 1980-05-14 Bayer Ag Verfahren zur herstellung von 1,4-dihydropyridincarbonsaeuren sowie ihre verwendung als arzneimittel
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4269859A (en) * 1979-04-19 1981-05-26 Brown Company Cellulose floc granules and process
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet

Also Published As

Publication number Publication date
GB2053681B (en) 1984-04-04
IT8023228A0 (it) 1980-07-03
DE3024858C2 (de) 1996-02-29
US4673564A (en) 1987-06-16
ES8200557A1 (es) 1981-11-16
CA1146866A (en) 1983-05-24
ES493152A0 (es) 1981-11-16
GB2053681A (en) 1981-02-11
FR2460667B1 (sv) 1983-07-29
US4343789A (en) 1982-08-10
DE3024858A1 (de) 1981-01-22
SE8004938L (sv) 1981-01-06
IT1132169B (it) 1986-06-25
FR2460667A1 (fr) 1981-01-30
CH648484A5 (de) 1985-03-29
US4404183A (en) 1983-09-13

Similar Documents

Publication Publication Date Title
JP2528706B2 (ja) ジヒドロピリジン化合物の製剤組成物
US4404183A (en) Sustained release pharmaceutical composition of solid medical material
US5340589A (en) Low solubility drug-coated bead compositions
CZ2002724A3 (cs) Farmaceutický přípravek obsahující derivát benzamidu se zlepąenou rozpustností a orální absorptivitou
JP2001518083A (ja) アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化
US10004719B1 (en) Solid dispersion formulation
WO2002043704A1 (fr) Composition a solubilite ou absorbabilite orale amelioree
US20240173310A1 (en) Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
BRPI0720937A2 (pt) Dispersão sólida de um antagonista de neuroquinina
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
KR920006908B1 (ko) 디히드로피리딘을 함유하는 고상 약제의 제조 방법
JP2000514057A (ja) 増強されたバイオアベイラビリティを有する抗真菌剤の固溶体
JP2003500439A (ja) 脂質調節剤を含む新規調合物
JPH04360833A (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
JPH04210638A (ja) 流体形態で経口投与するための医薬調製物
EP0410422A2 (en) A highly absorbable pharmaceutical composition
JP2001511796A (ja) 環状四級アンモニウム化合物を経口投与するための乾燥形態の薬学的調合剤
US5266581A (en) Solid composition containing dihydropyridine, PVP and PVPP
JPH029007B2 (sv)
JPH11335302A (ja) 安定な医薬組成物
IL134378A (en) A complex that neutralizes the charge of aprosartan arginine, its preparation and pharmaceutical preparations containing it
PT2468256E (pt) Combinações de vildagliptina e glimepirida
JPH05139973A (ja) ニフエジピン含有固形製剤の製造方法
EP3796899B1 (en) Novel pharmaceutical composition of tamsulosin and dutasteride
HK40099695A (zh) 包含(4s)-2⁴-氯-4-乙基-7³-氟-3⁵-甲氧基-3²，5-二氧代-1⁴-(三氟甲基)-3²h-6-氮杂-3(4，1)-吡啶-1(1)-[1，2，3]三唑-2(1，2)，7(1)-二苯七蕃-7⁴-甲酰胺的药物剂型

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8004938-0

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8004938-0

Format of ref document f/p: F